Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LiveSpo Navax for preventing respiratory diseases in children
NCT06148194Completed
- Sponsor
- AnaBio Technologies
- Start
- Jan 2024
- Primary completion
- May 2024
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial of bacillus subtilis and bacillus clausii in Respiratory Disease (RD) and respiratory tract infection (RTI), sponsored by AnaBio Technologies. Primary endpoints: Percentage of children with respiratory infections at 4 weeks and Incidence of medication intakes (%) at 4 weeks. Started Jan 2024; status: completed.
02
Drugs
bacillus subtilisbacillus clausii
03
Conditions
Respiratory Disease (RD)respiratory tract infection (RTI)
Beyond the preview
Go deeper on NCT06148194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06148194.